LACTOLOGY FOUNDATION

ATC A02AD01 – Ordinary Salt Combinations

Antacids in class A02AD01 are “ordinary salt combinations” of aluminum, calcium, and/or magnesium compounds formulated to neutralize gastric acid in dyspepsia and gastroesophageal reflux. These products typically combine calcium carbonate and magnesium salts (e.g., magnesium carbonate or hydroxide), sometimes with additional aluminum salts or adsorbent clays such as attapulgite.

In Bulgaria, this ATC level currently corresponds to fixed-dose combinations such as heavy calcium carbonate plus heavy magnesium carbonate tablets (e.g., GATTARD 680 mg/80 mg), which represent a typical “ordinary salt combination” profile. These formulations provide rapid symptom relief through direct acid neutralization, without systemic suppression of acid secretion.

Mechanism of Action and Pharmacokinetics

Calcium carbonate and magnesium carbonate react chemically with hydrochloric acid in the stomach to form water and neutral salts, thereby raising intragastric pH and reducing pepsin activity. Calcium carbonate is a potent, fast-acting antacid, whereas magnesium salts tend to act more rapidly but for a shorter duration and may exert an osmotic laxative effect.

Systemic absorption of magnesium carbonate from the gastrointestinal tract is low, with most of the dose remaining within the intestinal lumen and being eliminated in the feces. Calcium from calcium carbonate is absorbed to a clinically relevant extent, especially when taken with food or in repeated high doses, which may contribute to hypercalcemia or milk‑alkali syndrome in predisposed patients.

General Toxicology Profile

In adults with normal renal function, short-term use of ordinary salt combinations at recommended doses is generally well tolerated. Excessive or prolonged intake, especially in the context of renal impairment or high calcium intake from other sources, can lead to hypermagnesemia, hypercalcemia, metabolic alkalosis, and nephrocalcinosis.

Magnesium toxicity manifests with neuromuscular depression, hypotension, bradycardia, and in severe cases respiratory paralysis, with risk highest in patients with reduced glomerular filtration. Chronic high-dose calcium carbonate exposure has been associated with milk‑alkali syndrome characterized by hypercalcemia, metabolic alkalosis, and renal dysfunction, particularly when combined with vitamin D or other calcium sources.

Reproductive Toxicology and Pregnancy

Magnesium and calcium salts used as antacids have long clinical experience in pregnancy and are generally considered low risk when used intermittently at therapeutic doses. FDA pregnancy category B indicates that animal studies have not demonstrated fetal risk and adequate human studies are lacking, but available data do not indicate an increased rate of congenital anomalies.

However, prolonged or high-dose parenteral magnesium sulfate use (different route and indication) has been associated with neonatal hypocalcemia and bone abnormalities, underscoring that cumulative magnesium load in pregnancy should be carefully monitored. For oral A02AD01 antacids, occasional short-term use is generally acceptable in pregnancy, but avoidance of chronic high-dose regimens and adherence to product-specific maximum daily doses is recommended.

Lactation Pharmacology

Magnesium carbonate displays low oral bioavailability, and ingested magnesium does not significantly concentrate in breast milk; mean physiological magnesium levels in human milk are about 31 mg/L (range 15–64 mg/L) and are not materially altered by maternal intake. Consequently, standard references classify magnesium carbonate as compatible with breastfeeding, with “very low risk” for the nursing infant when used at usual doses.

Calcium carbonate likewise shows limited transfer into breast milk relative to maternal exposure, and antacid products containing calcium carbonate (e.g., calcium carbonate chewable tablets) are generally considered safe in lactating women at recommended dosages. Overall, for healthy term infants, occasional maternal use of ordinary salt combinations in standard doses is unlikely to pose significant toxicological risk via breast milk.

Specific Lactation Risk Considerations

Despite the low passive transfer of magnesium and calcium into breast milk, certain A02AD01 products may contain specific magnesium complexes or mixed salts with less well‑characterized neonatal safety profiles. In the example of GATTARD 680 mg/80 mg, the formulation includes heavy calcium carbonate and heavy magnesium carbonate, but also a magnesium carbonate dihydroxide component described as relatively more toxic to newborns and predictably excreted in breast milk.

The manufacturer of GATTARD lists use in pediatric patients under 11 years as contraindicated, which, in the context of its composition and your internal toxicological criteria, supports categorizing it as incompatible with breastfeeding (Lactation Toxicology Category IV: plasma:milk ratio ≥1 and/or strongly toxic profile for mother and newborn). In such cases, breastfeeding should be discontinued or, preferably, a safer lower‑toxicity antacid alternative should be selected during lactation.

Clinical Use and Monitoring in Lactation

For most A02AD01 preparations based on conventional magnesium and calcium salts, short-term, on-demand use by breastfeeding mothers generally requires no interruption of breastfeeding or special timing relative to feeds. Nevertheless, chronic or high-dose use should be avoided, and particular caution is warranted in mothers of premature or medically fragile newborns who may exhibit increased intestinal absorption and sensitivity to magnesium.

Clinical monitoring should focus on maternal gastrointestinal tolerance (diarrhea from magnesium, constipation from calcium), renal function, and cumulative exposure from other magnesium or calcium‑containing medications or supplements. When a specific A02AD01 product is contraindicated in children or flagged as higher risk (as with GATTARD in your local context), a non‑systemic alternative with a more favorable lactation safety profile should be preferred.

Summary for Healthcare Professionals

Antacids in ATC class A02AD01 (ordinary salt combinations) provide rapid relief of acid‑related symptoms via direct neutralization of gastric acid by combinations of calcium and magnesium salts. Standard magnesium and calcium carbonate‑based preparations have a longstanding safety record in pregnancy and are generally considered compatible with breastfeeding at recommended doses, due to low systemic absorption of magnesium and limited transfer into breast milk.

Nonetheless, product‑specific composition and labeling must be carefully reviewed, as some combinations (e.g., those including specific magnesium carbonate dihydroxide components and contraindications in children under 11 years) may warrant a high lactation risk categorization and are best avoided in breastfeeding women. Selection of safer alternatives, avoidance of chronic high-dose use, and attention to maternal renal function remain central to minimizing toxicological risk for both mother and infant.